These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32255405)

  • 1. The clinical and laboratory investigation of dysbetalipoproteinemia.
    Boot CS; Luvai A; Neely RDG
    Crit Rev Clin Lab Sci; 2020 Nov; 57(7):458-469. PubMed ID: 32255405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.
    Boot CS; Middling E; Allen J; Neely RDG
    Clin Chem; 2019 Feb; 65(2):313-320. PubMed ID: 30538126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
    Koopal C; Marais AD; Visseren FL
    Curr Opin Endocrinol Diabetes Obes; 2017 Apr; 24(2):133-139. PubMed ID: 28098593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.
    Marais D
    Curr Opin Lipidol; 2015 Aug; 26(4):292-7. PubMed ID: 26103610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simplified diagnosis algorithm for dysbetalipoproteinemia.
    Paquette M; Bernard S; Blank D; Paré G; Baass A
    J Clin Lipidol; 2020; 14(4):431-437. PubMed ID: 32631794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
    Heidemann BE; Koopal C; Baass A; Defesche JC; Zuurbier L; Mulder MT; Roeters van Lennep JE; Riksen NP; Boot C; Marais AD; Visseren FLJ
    Clin Genet; 2022 Oct; 102(4):253-261. PubMed ID: 35781703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.
    Koopal C; Marais AD; Westerink J; Visseren FL
    J Clin Lipidol; 2017; 11(1):12-23.e1. PubMed ID: 28391878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.
    Blom DJ; Byrnes P; Jones S; Marais AD
    J Lipid Res; 2003 Jan; 44(1):212-7. PubMed ID: 12518040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum of type III hyperlipoproteinemia.
    Sniderman AD; de Graaf J; Thanassoulis G; Tremblay AJ; Martin SS; Couture P
    J Clin Lipidol; 2018; 12(6):1383-1389. PubMed ID: 30318453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia.
    Hazzard WR; Warnick GR; Utermann G; Albers JJ
    Metabolism; 1981 Jan; 30(1):79-88. PubMed ID: 7464557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.
    Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
    Ann N Y Acad Sci; 1985; 454():209-21. PubMed ID: 3000263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
    Smelt AH; de Beer F
    Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL; East C; Grundy SM
    Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm.
    Kei A; Miltiadous G; Bairaktari E; Hadjivassiliou M; Cariolou M; Elisaf M
    World J Clin Cases; 2015 Apr; 3(4):371-6. PubMed ID: 25879010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
    Murase T; Okubo M; Takeuchi I
    J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling.
    Corsetti JP; Love TM; Sparks CE; Bakker SJL; Dullaart RPF
    Clin Biochem; 2018 Sep; 59():31-36. PubMed ID: 29928902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis.
    Havel RJ
    Med Clin North Am; 1982 Mar; 66(2):441-54. PubMed ID: 7040846
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.